December 2022

tofacitinibまたはTNF阻害薬で治療中の関節リウマチ患者における静脈血栓塞栓症を予測するバイオマーカー

RMD Open. 2022;8(2):e002571 doi: 10.1136/rmdopen-2022-002571

Weitz, et al. analyse 291 protein biomarkers and three genetic markers and do not identify a clear mechanistic explanation for higher rates of venous thromboembolism (VTE) with tofacitinib in the ORAL Surveillance study.

Keywords:

July 2022

JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis

Front Med (Lausanne). 2022 doi: 10.3389/fmed.2022.859330

Promising results for patients with diffuse cutaneous systemic sclerosis (dcSSc) skin fibrosis and digital ulcers (DU), using JAK1/2 inhibitor baricitinib.

Keywords:

May 2022

関節リウマチ関連間質性肺炎に対するJAK阻害薬または アバタセプトの効果を検討した後方視的研究

Inflammopharmacology. 2022. Epub ahead of print doi: 10.1007/s10787-022-00936-w

This study of the effectiveness of JAKinibs or abatacept in patients with RA-interstitial lung disease (RA-ILD) shows that treatment is related to stability or improvement of RA-ILD in over 80% of patients.

Keywords:

April 2022

ウパダシチニブ使用中の関節リウマチ患者における13価 肺炎球菌ワクチンに対する反応性評価: フェーズ2 オープンラベル延長試験結果

RMD Open. 2022;8(1):e002110 doi: 10.1136/rmdopen-2021-002110

Vaccine sub-study of the BALANCE-EXTEND upadacitinib trial finds that approximately two-thirds of patients receiving upadacitinib 15 mg once-daily achieve a satisfactory humoral response to pneumococcal 13-valent conjugate (PCV-13) vaccine, despite receiving concomitant methotrexate (MTX).It is well known that a weakened immune response, comorbidities and immunosuppressant drug therapy all contribute to an increased susceptibility to infections in patients with RA. Likewise, the morbidity and mo...

Keywords: